Available Studies

We are offering $25 referral bonuses for studies 243631 and 244436. Refer a friend today!

· Your referral must be new to PAREXEL (or has not screened with us in the past 2 years)

· Referral must give the full name of the person who referred him or her AT the time of scheduling on the phone only

· Referral must complete and pass the screening visit

Jul 1 -30

Join the Baltimore Early Phase Unit in an upcoming study to evaluate the safety and tolerability of a new inhaler formulation compared to Pulmicort Flexhaler dry-powder inhaler (DPI) for the potential treatment of asthma.

You must weigh between 110 lbs - 220 lbs

This study involves

1 screening visit; spirometry and inhalation training at screening

Stay in-house 3 days/ 2 nights, go home for 2 days, return to stay in-house 3 days/ 2 nights again

1 outpatient visit

*Screening could last 4 hours or more*

Screening dates for cohort 7: Jul 16-19 and 22-23

Cohort 7 (In-house stay): Jul 25-27 and Jul 30- Aug 01

Screening dates for cohort 8: Jul 24-26 and 29

Cohort 8 (In-house stay): Jul 31- Aug 02 and Aug 05-07

This study involves:

• An initial in-house stay of 3 days/2 nights in-house stay, go home for 7 days, and another in-house stay of 3 days/2 nights
• 1 outpatient visit within 4-7 days after last dose

The purpose of this study is to evaluate the safety and tolerability of an investigational drug with food and without food, for the potential treatment of psoriasis.

• Screening dates for Cohort 4: Jul 12-18
• Cohort 3- In-House Stays: Jul 22-24 and Aug 1-3

• Screening dates for Cohort 5: Jul 19-25
• Cohort 3- In-House Stays: Jul 29-31 and Aug 8-10

We are seeking healthy normal volunteers between the ages of 18 and 50 to participate in a clinical trial that will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple IV infusions of two dose levels of an investigational drug that is being designed to treat Lupus. This study involves 2 screening visits, 3 in-house stays of 3 days/2 nights, and 7 outpatient visits.

Cohort 1a Admission: August 6, 2019

We are seeking healthy volunteers between the ages of 21 and 55 to participate in a clinical trial that will assess the potential interactional between an investigational drug and alcohol. This study involves 1 screening visit, 4 in-house stays of 6 days/5 nights, and 8 outpatient visits. You must have a history of regular alcohol consumption and able to consume 3 to 4 standard drinks on 1 occasion.

First Admission: August 12, 2019

This study involves:

• An initial in-house stay of 6 days/5 nights in-house stay, go home for 5 days, and another in-house stay of 12 days/11 nights
• 1 outpatient follow-up phone call

Screening starts 28JUN2019

Cohort 1:

Admission 1: 21JUL2019 - 26JUL2019

Washout : 5days

Admission 2 : 01AUG2019 -13AUG2019

Follow-up phone call: 12SEP2019

Cohort 2:

Admission 1 : 05AUG2019 - 26JUL2019

Washout : 5 days

Admission 2 : 16AUG2019 - 28AUG2019

Follow-up phone call: 27SEP2019

Join us in an upcoming study to evaluate the safety of an investigational drug when given with two other drugs used to treat gastroesophageal reflux disease (GERD).

This study involves 1 screening visit, [1] in-house stay of 24 days/23 nights and 1 telephone call.

Screening: Jul 15-17, 22-23

Cohort 2: 28Jul-20Aug

We are seeking healthy normal volunteers between the ages of 18 and 55 to participate in a clinical trial for the treatment against diphtheria toxin. The study involves 1 screening visit, 1 in-house stay of 5 days/4 nights and 6 outpatient visits. If you qualify, you can earn up to $3,600 for completing the study.

Admission dates: 11JUL2019; 16JUL2019; 18JUL2019

This study involves 2 screening visits, 1 in-house stay of 9 nights / 8 days and 1 outpatient follow-up. The 2nd screening visit will be scheduled upon receipt of genotype lab results (within 10-20 days of 1st visit). no study participation for 90 days prior to screening You must be of African Descent.

Cohort 27: Screen 17Jul in house stay 29 Jul - 6 Aug Follow up 13 Aug

Cohort 28: Screen 17,22,23,24 Jul in house stay Aug 5-13 Follow up 20 Aug

Cohort 29: Screen 22,23,24,29,30,31 Jul in-house stay 11-20 Aug Follow up 27 Aug

Cohort 30: Screen 22,23,24,29,30,31 Jul 5,6,7 Aug in-house stay 18-27 Aug Follow up 03 Sep

We are seeking healthy normal volunteers between the ages of 18 and 50 to participate in a clinical trial for a new investigational medication. The study involves 1 screening visit, 1 in-house stay of 15 Days/ 14 Nights and 4 outpatient visits. If you qualify, you can earn up to $4600 for completing the study.

Screening on: June 26th

Admission dates: July 8th, July 11th, July 14th

This study is for patients with definite idiopathic PD taking oral PD medication. The purpose of this study is to learn about the safety, tolerability, and pharmacokinetics (the amount of drug exposure in your body determined through blood tests) of ABBV-951 at four dose levels in patients with Parkinson’s Disease given as 72 hour subcutaneous (under your skin)infusions using infusion sets and syringe pumps. To take part, you will be required to complete 1 screening visit. If you qualify after the screening visit, site staff will contact you regarding when you will be able to start the study.

Study dates flexible

The purpose of this study is to assess the safety and tolerability of an investigational drug in subjects with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study drug is a type of antibody that is directed against a specific receptor within the immune system that has been found to be involved in systemic autoimmune diseases such as SLE and RA.

Volunteers in the study will receive a single dose of the study drug via an IV (intravenous) infusion. To determine if you qualify for the study you must first complete a screening visit.

Participation in this study involves 1 screening visit, 1 inpatient admission to our clinic for 2 days/1 night for dosing, and a minimum of 8 outpatient visits spread out over 16 weeks.

Visit dates are flexible

This study is for patients with progressive or relapsing forms of multiple sclerosis. The purpose of this study is to learn about the safety, efficacy, and pharmacokinetics of elezanumab at two dose levels in patients with multiple sclerosis. To take part, you will be required to complete 2 screening visits. If you qualify after the screening visits, site staff will contact you regarding when you will be able to start the study. This study consists of 17 office visits over 76 weeks in addition to a 30-day screening period

Study Dates are Flexible

Join a contact registry for upcoming Parkinson's Disease studies!

Study dates TBD

Join a contact registry for upcoming Rheumatoid Arthritis studies!

Study dates TBD

Join a contact registry for upcoming Lupus studies!

Study Dates TBD